NVS Jan 2024 75.000 call
| Previous close | 12.70 |
| Open | 12.80 |
| Bid | 18.60 |
| Ask | 23.50 |
| Strike | 75.00 |
| Expiry date | 2024-01-19 |
| Day's range | 12.70 - 12.90 |
| Contract range | N/A |
| Volume | |
| Open interest | 105 |
ZacksNovartis (NVS) Sandoz Presents Standalone Growth Strategy
Novartis generic arm, Sandoz, which will be spun off, expects strong growth as a standalone company, driven by increasing contribution from biosimilars.
ZacksFDA Accepts Vertex (VRTX), CRISPR's BLA Filings for Exa-Cel
The FDA grants priority review to Vertex (VRTX)/CRISPR's (CRSP) filings for exa-cel in SCD, with a final decision expected in December.
ZacksMerck's (MRK) Keytruda for Liver Cancer to Undergo FDA Review
FDA accepts Merck's (MRK) supplemental biologics license application for Keytruda plus chemotherapy for the treatment of patients with first-line advanced or metastatic biliary tract cancer.
ZacksZacks.com featured highlights include Toll Brothers, Walmart, W.W. Grainger, Novartis and Graphic Packaging Holding
Toll Brothers, Walmart, W.W. Grainger, Novartis and Graphic Packaging Holding are part of the Zacks Screen of the Week article.
Zacks5 Dividend Growth Stocks to Buy for Outperformance
Toll Brothers (TOL), Walmart (WMT), W.W. Grainger (GWW), Novartis (NVS) and Graphic Packaging (GPK) could be compelling picks for outperformance amid market volatility.
GlobeNewswireSandoz presents compelling investment proposition as standalone company at Capital Markets Day
Sandoz well positioned to deliver continued mid-single digit sales growth; core EBITDA margin of 24-26% and Free Cash Flow to more than double over mid term European champion committed to further extending global leadership in attractive and growing generics and biosimilars market, via purpose-driven strategy with focus on access and sustainability Six strategic levers to drive long-term investor value; attractive financial outlook, including targeted investment grade credit profile and progress
Motley FoolIs Novartis a Good Stock to Buy Right Now?
Novartis (NYSE: NVS) is a company in transition. Now, Novartis is close to completing this long-winded transition with the upcoming spin-off of its generic drug business, Sandoz, later this year. With a debt-to-equity ratio of 47%, Novartis' balance sheet isn't overly levered, especially compared to many of its big pharma peers.
ZacksIntercept (ICPT) Announces Positive Data From PBC Study
Intercept Pharmaceuticals (ICPT) announces new data showing the potential of a fixed-dose combination of OCA and bezafibrate to normalize multiple biomarkers in primary biliary cholangitis.
ZacksMerck (MRK) Sues US Government to Halt Drug Price Negotiations
Merck (MRK) files a lawsuit against claiming that the federal government is violating the Constitution by forcing drugmakers to negotiate prices at below market rates.
ZacksBausch (BHC) Down on Tentative Approval to Xifaxan ANDA
Bausch (BHC) declines after the FDA grants tentative approval to Norwichs ANDA for a generic version of Xifaxan.
ZacksNovo Nordisk and Golden Entertainment have been highlighted as Zacks Bull and Bear of the Day
Novo Nordisk and Golden Entertainment are part of the Zacks Bull and Bear of the Day article.
ZacksBiogen (BIIB) to End One of Two Parkinson's Studies on BIIB122
Biogen (BIIB) is now set to focus on the LUMA study on its and partner Denali Therapeutics' (DNLI) small molecule LRRK2 inhibitor, BIIB122, for Parkinson's
ZacksModerna (MRNA), Merck's Cancer Jab Delays Melanoma Spreading
Updated data from a mid-stage study showed that Moderna (MRNA)/Merck's personalized cancer vaccine combined with Keytruda reduces the skin cancer's spreading by 65% in melanoma patients.
ZacksNovartis Announces Positive Data on Breast Cancer Drug Kisqali
Novartis' (NVS) Kisqali reduces the risk of recurrence by 25% among patients with early breast cancer.
- Zacks
Oncorus (ONCR) Dips 37% on Layoff Plan & Bankruptcy Threat
Oncorus (ONCR) decides to lay off nearly all of its workforce since it is facing challenges in raising additional capital. This lay off is expected to be completed by August 2023.
ZacksWhy Novartis (NVS) is a Great Dividend Stock Right Now
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Let's find out.
- Zacks
Novo Nordisk (NVO) Gears Up to Acquire BIOCORP for 154M Euros
Novo Nordisk (NVO) enters into negotiations to acquire a majority stake in BIOCORP, followed by a tender offer to acquire all remaining shares in BIOCORP for a total equity value of 154 million Euros.
- Zacks
AstraZeneca (AZN) Anticoagulant Drug Study Meets Efficacy Goal
At the interim analysis, AstraZeneca's (AZN) drug Andexxa showed superior hemostatic efficacy or in other words improved control of bleeding with targeted anticoagulation reversal versus usual care.
ZacksFDA Expands AstraZeneca (AZN) Lynparza Label in Prostate Cancer
Following FDA's label-expansion approval, AstraZeneca's (AZN)/Merck's (MRK) Lynparza is the first PARP inhibitor approved in combination with a new hormonal agent in mCRPC.
ZacksHere's Why Novartis (NVS) Is a Great 'Buy the Bottom' Stock Now
After losing some value lately, a hammer chart pattern has been formed for Novartis (NVS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
GlobeNewswireNovartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups
Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of patients with HR+/HER2- early breast cancer, regardless of disease stage, menopausal or nodal status1 Results were also consistent across all secondary endpoints, including distant disease-free survival and recurrence-free survival, with a trend for improved overall survival*1 The safety profile of Kisqali was favorable at 400 mg with low rates of symptomatic adv
ZacksBayer (BAYRY) & Cedilla to Co-Develop Novel Cancer Therapies
Bayer (BAYRY) announces licensing agreement with Cedilla Therapeutics to jointly develop and commercialize the latter's selective protein complex inhibitors as novel cancer therapies.
ZacksBristol Myers (BMY) Loses 10.5% Year-to-Date: What Lies Ahead?
Bristol-Myers' (BMY) top drugs, Revlimid and Eliquis, face challenges. It remains to be seen if the approval of new drugs can fuel growth and offset declines.
ZacksAstraZeneca (AZN) Discontinues Brazikumab Development
AstraZeneca (AZN) announces its decision to discontinue the development of brazikumab for all indications under its inflammatory bowel disease program.
ZacksZacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novo Nordisk, Roche and Novartis
Eli Lilly, Johnson & Johnson, Novo Nordisk, Roche and Novartis have been highlighted in this Industry Outlook article.
